The stock of International Game Technology PLC (IGT) decreased by -0.08% to finish the standard trading session at $25.20. During that period, a total of 6,705,967 shares were traded, and this stock’s average trading volume is currently 2.25M shares per day. Important things to pay attention to when considering a stock’s current and future price are the 52-week high and low price points. Shares of International Game Technology PLC (IGT) are currently 45.50% above their 52-week high mark and -18.71% lower than the 52-week low mark.
POINT72 ASSET MANAGEMENT, L.P. opened a new position with shares of International Game Technology PLC (IGT) during the 1st quarter, according to the public company’s latest Form 13F filing with the US Securities and Exchange Commission (SEC). This particular institutional investor became the owner of 8,581,300 shares of the International Game Technology PLC stock, which is currently worth approximately $216.42M. According to the latest SEC filing from POINT72 ASSET MANAGEMENT, L.P., the firm held approximately 5.83% of International Game Technology PLC. On a separate note, OPPENHEIMERFUNDS, INC. Can entered a new position in International Game Technology PLC stock during the first quarter, holdings valued at $162.511M. Institutional investors and hedge funds hold 42.20% of this public company’s common stock.
Turning now to this publicly-traded company’s past performance, we will explore different moving trends for IGT. This stock fell -1.49% during the last week and fell -14.17% over the last one-month period. Shares of this organization’s stock fell -18.02% throughout the last quarter. Within the last six months, the stock has lost -8.03%, with a full-year gain of 36.66%. At the time of writing, this stock’s year-to-date (YTD) price performance is now negative at -4.94%.
Out of a total of 7 brokerages that are currently covering International Game Technology PLC (IGT) stock, the average recommendation is Buy, according to reuters. 0 equities research analyst has rated the stock with a “Underperform” recommendation, 5 analysts have given this stock a “Buy” recommendation, 1 analysts have recommended that investors “Hold” this stock, and 0 analysts have given this stock a “Sell” rating. Analysts’ average 1-year price target, among all the brokerages, is $33.67.
Shares of AbbVie Inc. (ABBV) managed to reach a high of $99.23 and dropped down to a low of $97.52, before this stock settled at $97.58 at the end of the latest trading session. This organization’s stock has been displaying bullish momentum. Its Average True Range, or ATR, has fallen consistently after each of the most recent 10 trading sessions. Stock traders typically look at the ATR when they want to focus on technical analysis. At the time of writing, the 14-day ATR for AbbVie Inc. (ABBV) is sitting at 2.02. AbbVie Inc. currently has a 52-week low of $40.67% with a 52-week high of -$22.47%. This organization has a debt-to-equity ratio of 10.49, a quick ratio of 1.10, and a current ratio of 1.20. This public company has a market cap of 155.25B, a beta of 1.59a price-to-earnings-growth ratio of 0.94, and price-to-earnings ratio of 15.69.
Schumacher Laura J, the Executive Vice President of AbbVie Inc. (ABBV), sell 25,000 shares of ABBV stock in an exchange that took place on Mar 01. The shares were sell at an average price of $117.85 each, amounting to a total sale worth $2,946,148. As of the close of the sale, the Executive Vice President now directly holds 98,317 shares of the organization’s stock, which is now worth about $11.58665845M. The deal was disclosed in a Securities & Exchange Commission legal filing, which can be publicly viewed on the SEC website.
AbbVie Inc. (ABBV) most recently publicly disclosed its earnings results on 04/26/2018. The organization posted ($1.87) earnings per share (EPS) during the three-month period, which was $0.08 lower than the consensus estimate of ($1.79). The company experienced a negative return on equity of 119.30% and a positive net margin of 21.50%. AbbVie Inc. reported revenue of 7,934.00 million during the quarter, while the average analyst estimate was 7,588.20 million. During the year-ago quarter, the company reported ($1.48) EPS. The quarterly revenue reported by AbbVie Inc. was down $0.04 compared to the same quarter in the previous year. Analysts forecast that AbbVie Inc. will report EPS of $1.44 for the current fiscal year.
Stock traders are taking a renewed look at shares of AbbVie Inc.. This stock’s current 20-day RSI is standing at 44.07, with a 14-day RSI of 41.42, and a 9-day RSI of 36.41. The RSI, which stands for Relative Strength Index, is a widely-used oscillating indicator trusted by investors and traders alike. The RSI works within a range-bound space with values on a scale from 0 to 100. When the RSI line rises, the shares may be showing strength. The contrary is the case when the RSI line starts to fall. When using the RSI indicator, different time periods may be looked at. When using a shorter time frame, the RSI might be more volatile. A lot of traders keep their focus between the 30 and 70 marks on the RSI scale. A shift higher than 70 is widely-considered to demonstrate that the stock has entered overbought territory. Meanwhile, a drop below 30 indicates that it may be in oversold territory. Traders often use these levels to predict stock price reversals.